FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives

Key Takeaways

• FDA CBER held a dedicated patient listening meeting focused on two core themes: safety considerations in gene therapy treatment decisions and partnering on long-term studies after gene therapy administration.
• Patients and care partners shared perspectives through structured sessions, with FDA staff posing follow-up questions to clarify concerns and expectations regarding approved gene therapies for rare diseases.
• FDA signaled broader strategic efforts to support gene therapy development, including establishment of an FDA Rare Disease Hub, collaboration with NCATS and the Bespoke Gene Therapy Consortium, and global coordination with European regulators and the World Health Organization.
• A public docket (FDA-2024-N-3208) remained open through November 19, 2024, to capture additional feedback that will inform a meeting summary.

Why This Matters for Pharma Teams

The listening meeting highlights the safety questions and long-term monitoring expectations that patients and care partners want addressed before and after gene therapy treatment. FDA's emphasis on patient-centered perspectives may influence how developers design post-market evidence strategies and communicate risk-benefit information. The meeting underscores FDA's interest in understanding real-world patient preferences for information delivery—including preferences for healthcare providers, manufacturers, patient advocacy organizations, and scientific literature—which can inform regulatory submissions and patient engagement materials. For clinical, regulatory, and medical affairs teams, the session structure and polling questions provide insight into how FDA prioritizes patient input in rare disease gene therapy development and approval.

Meeting Structure and Content

The meeting comprised two main sessions organized around patient and caregiver decision-making. Session 1 focused on safety considerations in treatment decisions, while Session 2 addressed partnering on long-term studies after gene therapy. FDA leadership, including CBER Director Dr. Peter Marks, opened the meeting with remarks on the Agency's commitment to advancing genetic medicine and its collaborative efforts with internal and external partners. Introductory polling questions captured participant demographics, knowledge levels, and preferences for receiving information about gene therapy risks.

Frequently Asked Questions

What was the primary purpose of this FDA listening meeting?

The FDA CBER convened the meeting to hear directly from patients, caregivers, and advocates about their perspectives on safety considerations for approved gene therapies and long-term follow-up expectations. FDA staff used patient input to better understand concerns and inform the Agency's strategy moving forward.

How can stakeholders provide feedback if they did not attend the meeting?

A public docket (FDA-2024-N-3208) on www.regulations.gov remained open through November 19, 2024, to accept additional comments. Presentations and docket submissions were to be used to develop a meeting summary.

What collaborative efforts did FDA highlight regarding gene therapy development?

FDA CBER is collaborating with the Center for Drug Evaluation and Research (CDER) on an FDA Rare Disease Hub, with the National Center for the Advancement of Translational Sciences (NCATS) and the Bespoke Gene Therapy Consortium (BGTC) on manufacturing and clinical study advancement, and internationally with European regulators and the World Health Organization to expand access and support regulatory frameworks in underserved regions.

Who was invited to participate in the patient listening meeting?

Patients who have received gene therapy, patients considering available gene therapies, and care partners (defined as parents, spouses, family members, or close friends involved in care) were invited to share their perspectives during the structured sessions.

Related coverage

• $2M Gene Therapy Cures Need a Financing Model
• Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial